Headache attributed to a substance or its withdrawal.

Abstract

Medication overuse, and subsequent medication overuse headache (MOH), is a growing and still underestimated problem worldwide. A significant number of recent epidemiological studies suggest that up to 4% of the general population in Europe, North America, and Asia overuse analgesics and other drugs for the treatment of pain conditions such as migraine. These studies also provide convincing evidence that about 1% of the general population suffers from MOH. The condition can be caused by almost all antiheadache drugs, including analgesics, ergots, triptans, and combined preparations. The clinical symptoms of MOH are heterogeneous and may vary from just an increase in headache attack frequency to a constant holocranial pain over years. The International Headache Society (IHS) defined MOH in its first classification in 1988 but modified the diagnostic criteria in its second classification in 2004 to facilitate diagnosis and the conduct of clinical trials. The underlying pathophysiology of MOH is not well understood. The only therapy is withdrawal from the overused substances. The only strategy to reduce the prevalence of MOH is to prevent the development of MOH in the first place by clear restriction of monthly doses of antiheadache drugs and constant education of both patients and physicians prescribing or recommending antiheadache drugs.

• Authors: Hans-Christoph Diener, Zaza Katsarava, Volker Limmroth
• Journal: Handbook of clinical neurology (Handb Clin Neurol) Vol. 97 Pg. 589-99 ( 2010) ISSN: 0072-9752 [Print] Netherlands
• PMID: 20816457 (Publication Type: Journal Article)
• Copyright: Copyright © 2011 Elsevier B.V. All rights reserved.

Chemical References

• Analgesics

Topics

• Analgesics (administration & dosage)
• Headache (drug therapy)
• Headache Disorders, Secondary
• Humans
• Migraine Disorders
• Prevalence